Successfully navigating the stock market requires patience and a long-term perspective. The key is sticking to a consistent plan and making regular contributions to a retirement account, allowing the power of compounding to work its magic over time.
Nevertheless, there’s an undeniable allure in searching for potential multibagger stocks. Something is captivating about companies with disruptive innovations, whose stocks could be on the cusp of rapid growth and capable of delivering life-changing returns to shareholders.
Recursion Pharmaceuticals(NASDAQ: RXRX) is a clinical-stage biotech that may have that level of potential. The company harnesses artificial intelligence (AI) for drug discovery, promising to revolutionize medicine. Let’s explore whether buying the stock could eventually help you become a millionaire.
Recursion has rapidly established itself as a leader in the field of AI-enabled biotechnology. The company’s BioHive-2 supercomputer, powered by Nvidia AI chips, is one of the world’s most powerful accelerated computing systems.
Through advanced machine learning techniques, BioHive-2 analyzes vast amounts of biological data to identify drug targets, including proteins and genes involved in disease. Recursion’s operating system (OS) evaluates millions of compounds to identify potential drug candidates, while also predicting drug molecule properties and optimal patient populations to enhance drug design.
These efforts allow accelerated research on treatments across a wide range of conditions, while reducing costs compared to traditional methods.
A major development for Recursion this year was its merger with Exscientia, another biotech company focused on AI-based drug discovery. Exscientia’s expertise in advanced methods of chemical design complements Recursion’s biology-driven approach. This combination has created a vertically integrated platform, resulting in a fundamentally stronger company.
Image source: Getty Images.
The good news is that Recursion’s technology has already yielded promising results, with a robust pipeline of drug candidates that now incorporates Exscientia’s legacy programs.
One of the most promising prospects is REC-994, which could become the first oral therapy for treating symptomatic cerebral cavernous malformation (CCM), a brain hemorrhaging condition that currently lacks any approved treatments.
REC-617 has also shown encouraging results, with a recent phase 1 interim study demonstrating positive patient responses and good tolerability in treating advanced solid tumors. The company believes this drug has “best in class” potential, one of several reasons that make Recursion an intriguing opportunity for investors.
Looking ahead to 2025, the market will be closely following clinical readouts and regulatory updates as catalysts for Recursion stock:
Source: Recursion Pharmaceuticals.
It seems likely that at least one of Recursion Pharmaceuticals’ candidates could eventually gain approval as a novel therapy, transforming the company into a commercially sustainable operation over the next decade.
But making a much more bullish case for the stock, as an investment to multiply many times over, would be a significantly more challenging proposition. It would likely require Recursion to develop a blockbuster drug capable of generating billions of dollars in sales across multiple years.
The reality is that Recursion remains years away from bringing a drug to market. Currently, the company generates only limited revenue through partnership milestone payments and research grants, while facing substantially higher operating expenses. Wall Street analysts project continued financial losses for the foreseeable future, with negative earnings per share (EPS) expected to worsen from a projected loss of $1.54 this year to $1.65 in 2025.
Metric
2023
2024 (Estimate)
2025 (Estimate)
Revenue (in millions)
$44.6
$70.0
$76.0
Revenue change (YOY)
12%
57%
9%
Earnings per share (EPS)
($1.58)
($1.54)
($1.65)
EPS change (YOY)
N/A
N/A
N/A
Data source: Yahoo Finance. YOY = year over year.
While the market can overlook a lack of profitability based on longer-term growth prospects, the dynamic may keep the stock under pressure. Shares of Recursion are down approximately 55% from their 52-week high, and any sort of regulatory setback could send the stock even lower.
Another consideration is the highly competitive industry landscape. Major biotech and pharmaceutical companies like Merck, AstraZeneca, and Pfizer, among others, are increasingly using artificial intelligence in their research and development processes. This widespread adoption raises questions about whether Recursion can maintain a technological advantage in the field.
Although Recursion Pharmaceuticals offers compelling possibilities, I believe that without better visibility into its product approval pathway, it’s just too early to buy this stock with conviction. In the meantime, 2025 will be a crucial year for the company to offer more clarity on its long-term potential. You may want to keep this one on your radar.
Before you buy stock in Recursion Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Recursion Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $825,513!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. TheStock Advisorservice has more than quadrupled the return of S&P 500 since 2002*.
Dan Victor has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Merck and Pfizer. The Motley Fool recommends AstraZeneca Plc. The Motley Fool has a disclosure policy.
